Advertisement
Table 1 Age and age-adjusted baseline characteristics of cancer-free women and breast cancer survivors in the BOSS cohort study
| Characteristic | Cancer-free | Survivorsa | p Value |
|---|---|---|---|
| (n = 567) | (n = 211) | ||
| Ageb, years, mean (SD) | 44.7 (11.3) | 48.1 (10.3) | < 0.001 |
| Race, white, % | 88.7 | 83.3 | 0.02 |
| Education, ≥ 4 years of college, % | 77.6 | 77.4 | 0.72 |
| Postmenopausal, % | 27.4 | 51.6 | < 0.001 |
| Age at menopausec, years, mean (SD) | 49.6 (4.9) | 48.8 (3.4) | 0.86 |
| Bilateral oophorectomy at age < 45 yearsd, % | 49.0 | 34.3 | 0.02 |
| BMI, kg/m2, mean (SD) | 26.2 (5.1) | 25.9 (3.1) | 0.29 |
| Physical activity, MET-h/wke, mean (SD) | 29.4 (27.9) | 26.0 (15.5) | 0.29 |
| Alcohol intake, g/d, mean (SD) | 5.7 (7.5) | 5.7 (4.8) | 0.99 |
| Smoking status, % | |||
| Never | 58.8 | 52.5 | 0.55 |
| Former | 36.7 | 44.8 | |
| Current | 4.2 | 2.7 | |
| Missing | 0.3 | 0.0 | |
| HRT ever use, % | 15.1 | 14.5 | 0.04 |
| Ever mammogramf, % | 99.5 | 97.8 | 0.63 |
| Ever pap smear, % | 98.6 | 99.1 | 0.15 |
| Current vitamin D supplement use, % | 7.8 | 20.8 | < 0.001 |
| Current calcium supplement use, % | 25.5 | 28.1 | 0.97 |
| Bone density examination, % | 28.9 | 43.0 | 0.02 |
| Bone density examination in women aged ≥ 45 years, % | 51.2 | 60.0 | 0.08 |
| Ever broken bone, % | 6.4 | 6.8 | 0.84 |
| Family history of breast cancer, % | |||
| No family history | 14.7 | 38.9 | < 0.001 |
| First-degree relative only | 64.8 | 50.7 | |
| First- and second-degree relatives | 17.0 | 9.0 | |
| Missing | 3.5 | 1.4 | |
| BRCA1/2 statusg, % | |||
| Negative | 69.7 | 73.9 | 0.33 |
| Positive | 27.3 | 19.4 | |
| Variants of uncertain significance | 2.9 | 6.7 | |
| Age at diagnosis, years, mean (SD) | – | 46.8 (10.2) | – |
| Time from diagnosis to baseline, years, mean (SD) | – | 1.4 (1.3) | – |
| Invasive breast cancer (stage I–III), % | – | 82.5 | – |
| Estrogen receptor statush, % | – | – | |
| Positive | – | 75.9 | – |
| Negative | – | 23.6 | – |
| Missing/untested | – | < 1.0 | – |
| HER2 statush, % | – | – | |
| Positive | – | 14.4 | – |
| Negative | – | 81.6 | – |
| Missing/untested | – | 3.5 | – |
| Triple-negative statush, % | – | 19.0 | – |
| Breast cancer treatmenti,j, % | – | – | |
| Surgery | – | 100.0 | – |
| Chemotherapy | – | 49.8 | – |
| Hormone therapy, any | – | 65.4 | – |
| Hormone therapy, by typek | – | – | |
| Tamoxifen | – | 67.4 | – |
| Aromatase inhibitor | – | 41.3 | – |
